Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.
- DOI
- 10.1007/s13555-025-01543-7
- Published
- 2025 Dec
- Container
- Dermatology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-025-01543-7,
title = {Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.},
author = {King B and McMichael A and Sinclair R and Vañó-Galvan S and Wolk R and Woodworth D and Soma K and Robbana F and Lejeune A and Napatalung L and Law E and Wajsbrot D and Wang C and Roychoudhury S},
year = {2025},
journal = {Dermatology and therapy},
doi = {10.1007/s13555-025-01543-7},
url = {https://doi.org/10.1007/s13555-025-01543-7}
}RIS
TY - JOUR TI - Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata. AU - King B AU - McMichael A AU - Sinclair R AU - Vañó-Galvan S AU - Wolk R AU - Woodworth D AU - Soma K AU - Robbana F AU - Lejeune A AU - Napatalung L AU - Law E AU - Wajsbrot D AU - Wang C AU - Roychoudhury S PY - 2025 JO - Dermatology and therapy DO - 10.1007/s13555-025-01543-7 UR - https://doi.org/10.1007/s13555-025-01543-7 ER -
APA
B, K., A, M., R, S., S, V., R, W., D, W., K, S., F, R., A, L., L, N., E, L., D, W., C, W., & S, R. (2025). Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.. Dermatology and therapy. https://doi.org/10.1007/s13555-025-01543-7
Source records
- pubmed · retrieved 2026-09-26T08:53:32.349Z